Results of the LMM analysis for IOP change.

To analyze the surgical outcomes of iStent inject W (ISIW) implantation and investigate the influence of preoperative factors. In total, 114 eyes of 114 patients (mean age, 73.22 ± 7.84 y) were enrolled in this retrospective study. The patients underwent ISIW implantation at the Jikei University Hospital. The number of antiglaucoma medications was converted into glaucoma medication scores (GMS). Linear mixed model (LMM) analysis was performed by setting GMS and intraocular pressure (IOP) change as objective variables, and the postoperative days, preoperative mean deviation (MD), preoperative IOP, and various antiglaucoma medications as fixed effects. The preoperative IOP was 15.06 ± 3.51 mmHg and significantly reduced to 12.22 ± 2.23 mmHg at 3 months and 12.99 ± 2.45 mmHg at 12 months. The mean GMS was 2.46 ± 1.33 preoperatively, and decreased to 1.32 ± 1.31 at 3 months, and 1.60 ± 1.41 at 12 months postoperatively. The IOP and GMS values were based on a subset of 72 eyes with 12-months of complete follow-up data. LMM analysis showed significant coefficients for IOP change in relation to postoperative days and preoperative IOP, and for GMS change in relation to postoperative days, β blockers (BB), and Rho kinase inhibitors (ROCK inhibitors). Preoperative factors, particularly medication use, influenced outcomes, indicating that BB or ROCK inhibitors were associated with a greater reduction in the need for postoperative antiglaucoma medications.

本研究旨在分析iStent inject W（ISIW）植入术的手术结局，并探讨术前相关因素对手术疗效的影响。本回顾性研究共纳入114例患者的114只患眼，患者平均年龄为73.22±7.84岁，均在东京慈惠会医科大学附属医院接受ISIW植入术。研究中将抗青光眼药物的使用数量转换为青光眼药物评分（GMS）。以青光眼药物评分（GMS）与眼压（IOP）变化作为因变量，以术后随访天数、术前平均视野缺损（MD）、术前眼压及各类抗青光眼药物作为固定效应，开展线性混合模型（LMM）分析。术前眼压为15.06±3.51 mmHg，术后3个月显著降至12.22±2.23 mmHg，术后12个月眼压为12.99±2.45 mmHg。术前青光眼药物评分平均为2.46±1.33，术后3个月降至1.32±1.31，术后12个月降至1.60±1.41。本次分析的眼压与青光眼药物评分数据，来自72只拥有完整12个月随访数据的患眼亚组。线性混合模型分析结果显示，眼压变化与术后随访天数、术前眼压存在显著相关系数；青光眼药物评分变化与术后随访天数、β受体阻滞剂（BB）及Rho激酶抑制剂（ROCK抑制剂）存在显著相关系数。术前相关因素（尤其是用药情况）会对手术结局产生影响，提示使用β受体阻滞剂或ROCK抑制剂可更大程度降低术后抗青光眼药物的使用需求。